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Abstract
Recent advances in human transcriptome have revealed the fundamental and
functional roles of long non-coding RNA in the susceptibility to diverse diseases
and pathological conditions. They participate in wide range of biological processes
such as the modulating of chromatin structure, transcription, translation, and post-
translationmodification. In addition, based on their unique expression profiles and their
association with clinical abnormalities such as those of related to male reproductive
diseases, they can be used to develop therapeutic methods and biomarkers for
screening of the diseases. In this study, we will review the identified lncRNAs and
their molecular functions in the pathogenesis of male reproductive diseases such as
prostate cancer, benign prostatic hyperplasia, prostatitis, testicular cancer, varicocele,
and sperm abnormalities.
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1. Introduction
The prevalence of infertility is 15% worldwide,
and according to the global data, 20-70% of the
total infertility cases is attributed to male infertility
(1). Male infertility is characterized by heterogeneous
and multifactorial conditions among which genetics
factors encompass approximately 40% of cases with
idiopathic infertility (2). The most common clinical
abnormalities associated with male infertility are
prostate cancer (PCa), prostatitis, benign prostatic
hyperplasia (BPH), testicular cancer (TCa), varicocele,
and inability to produce normal sperm (azoospermia,
oligozoospermia, asthenozoospermia (AZS), and
teratozoospermia). Although the main molecular
mechanisms involved in the pathogenesis of these
abnormalities are unknown, all of them have genetic
background (3-6).
While more than 85% of the human genome
is transcribed, only a low proportion of these
transcribed RNAs encode proteins (7). Non-coding
RNAs (ncRNAs) are categorized into two broad
groups based on their size. Short ncRNAs are < 200
nucleotides (nts) in length and include microRNAs
(miRNAs), piwi-interacting RNAs (piRNAs), and small
nuclear RNAs (snoRNA) (8), while long ncRNAs
(lncRNAs) are > 200 nts in length (Figure 1).
lncRNAs are involved in several mechanisms
such as chromatin remodeling, chromatin looping,
recruitment of transcription factors. They can
also be involved in RNA splicing and control of
translation. Furthermore, they can also modulate
RNA degradation as well as act as a miRNA sponge
and sequester them to control gene expression
(Figure 2) (9).
The gene regulatory process can occur at
any stage such as RNA transcription, translation,
and post-translational modification. This process
includes DNA methylation, histone modification
(methylation, phosphorylation, ubiquitylation,
acetylation, and sumoylation) and tissue-specific
transcription factors (TFs) (10, 11). In addition,
ncRNAs have also been identified as prominent
regulatory elements in gene expression (12). The
dark matter of the genome, lncRNAs, was previously
considered as transcriptional noise (13). However,
advances in genomic technologies such as high-
throughput sequencing technologies have led
to the identification of thousands of lncRNA in
different diseases including male reproductive
ones. LncRNAs are involved in differentiation,
proliferation, and self-renewal of spermatogonial
stem cells (SSCs) (14). Furthermore, they modulate
apoptosis, invasion, cell cycle, and cell signaling
pathways in the male reproductive tract. Therefore,
LncRNAs could be considered as a potential
biomarker to detect any abnormalities in male
reproductive tract. In this review, we will provide a
short summary about the role of lncRNAs and their
pathways in the pathogenesis of male reproductive-
associated diseases such as PCa, prostatitis,
BPH, TCa, varicocele, and sperm abnormalities
(azoospermia, oligozoospermia, asthenozoospermia,
and teratozoospermia).
Figure 1. The components of the human genome. Less than 5% of the genome consists of coding sequences, which can ultimately
be translated to proteins. More than 95% of genome encompasses non-coding DNA, which is transcribed into two broad groups
including small ncRNA and lncRNA. Small ncRNAs are categorized into regulatory (rRNA: 121-5070 nts, tRNA: 73-93nts, snoRNA:
70-200 nts) and functional RNAs (miRNA: 21-25 nts, siRNA: 20-25 nts, piRNA: 24-31 nts). LncRNAs can act as cis-acting lncRNA
(affect nearby genes in same chromosome) or trans-acting lncRNA (affect distant gene on other chromosomes). LncRNA can
originate from sense, antisense strand, intergenic (lincRNA), and opposite direction to nearby protein (divergent).
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Figure 2. Functions of lncRNAs, (I) lncRNAs (in red) recruit chromatin modifiers such as activator (brown) or repressive (green)
Histon remarks to change chromatin organizational pattern. (II) They can act as a structure to create chromatin looping through
which, cis-regulatory sequences such as enhancers and silencers interact with target promoters. (III) LncRNAs control transcription
by interacting with transcriptional activators and repressors. (IV) LncRNAs canmodulate splicing pattern of RNA by interacting with
splicing factors and junctions. (V) LncRNAs control translation by inhibiting or favoring the loading of polysome to mRNAs. (VI)
LncRNAs protect RNA from degradation or subject them to degradation machinery. (VII) LncRNAs also act as molecular sponge
by interacting with their complementary miRNA. They can also occupy their binding sites on RNA molecules.
2. Materials and Methods
The current narrative review study aimed
to provide the latest information about the
lncRNAs involved in the susceptibility to different
male reproductive diseases and summarizing
lncRNAs functions in the development of
the related diseases. It was conducted
through a comprehensive search in electronic
databases, including PubMed, Scopus, and
Google Scholar using Keywords such as
lncRNA, prostate cancer, prostatic hyperplasia,
prostatitis, testicular cancer, varicocele, sperm
abnormalities. After evaluating 122 related
articles including original, review, and meta-




PCa as a complex and noncutaneous
malignancy is the second cause of cancer-
associated death among men (15). Several
studies have implicated the role of differentially
expressed lncRNAs affecting pathological,
treatment, and prognosis of PCa. In
addition, lncRNAs can act as oncogene
and tumor suppressor molecules in PCa
tumorigenesis (16, 17). We will discuss
some principal oncogenic lncRNAs later
in the article. Table I mentions the further
oncogenic lncRNAs with their summary of
functions.
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Table I. Other* known oncogenic lncRNAs involved in PCa
IncRNA Genomic location Summary of functions Reference
SAP30L-AS1 5q33.2 Binds to promoter of SAP30L and represses it. It promotesPCa cell proliferation and inhibits apoptosis (18)
FALEC 1q21.2 Up regulated in hypoxic environment. It promotes invasion,proliferation and migration in vitro (19)
MYU/VPS9D1-AS1 16q24.3 Promotes expression of c-Myc by competitive binding tomir-184. It induces proliferation of PCa (20)
PCSEAT/PRCAT38 21q22.3 By acting as a sponge for miRNA-143-3p and miRNA-24-2-5p,regulates EZH2. It increases the motility and growth of PCa (21)
FOXC2-AS1 16q24.1
Targets 3’UTR of miR-1253 and binds to complementary site




Knock down of this lncRNA with siRNA increases the
expression of genes such as GAPDH (regulates glycolysis),
MAP1LC3B2 (autophagy) and H2AFY (chromatin structure). It
increases cell proliferation of PCa
(23)
LOC400891 22q11.2
Up regulated in PCa tissue. It is associated with proliferation,
migration and invasion in PCa tissues and independent
predictor of biochemical free-survival
(24)
ncRNA-ROR 18q21.31
Acts as ceRNA and Competes with miR-145 binding in
HuPCaSCs (human prostate cancer stem cells), miR-145
decreases cell proliferation in PCa by suppressing Oct4
expression. It promotes cell proliferation in PCa
(25)
PCA3/DD3 9q21-22
Knock down of this lncRNA in LNCap cells regulates genes
encoding AR cofactors and EMT marker. It increases viability
of PCa cells
(26)
SPRY4-IT1 5q31.3 Highly upregulated in PCa. Knockdown of this lncRNA in PC3cells inhibits cell proliferation and invasion of cells (27)
LOC440040 11p11.12
Upregulated in PCa tissues, high expression of this lncRNA is
associated with advanced clinical features and shorter overall




Recruits methyltransferase MLL1 to promoter of ZEB1 and
increases expression of ZEB1 by inducing H3K4me3. It
increases proliferation and migration of PCa cells
(29)
TRPM2-AS 21q22.3
Overexpressed in PCa. In addition, it regulates TRPM2 gene
and genes related to cell cycle and survival such as FYN and
AKT1
(30, 31)
*Refers to lncRNAs which are not mentioned in the main text
Abbreviations: SAP30L: 30-kDa Sin3-associated Protein, EZH2: Enhancer of zeste homolog 2, UTR: Untranslated region, siRNA:
Small interfering RNA, GAPDH: Glyceraldehyde 3-phosphate dehydrogenase, MAP1LC3B2: Microtubule-associated proteins
1A/1B light chain 3 beta 2, H2AFY: H2A histone family member Y, HuPCaSCs: Human prostate cancer stem cells, LNCap: Lymph
node carcinoma of the prostate, AR: Androgen receptor, EMT: epithelial-mesenchymal transition, MLL1: myeloid/lymphoid or
mixed-lineage leukemia 1, ZEB1: Zinc finger E−box binding homeobox 1 TRPM2: Transient receptor potential cation channel
subfamily M member 2
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3.1.1. Oncogenic lncRNAs in PCa
Prsenter and colleagues identified 121
unannotated ncRNA transcript in a cohort of
102 prostate tissues and cell lines using high-
throughput RNA sequencing and named them
as prostate cancer-associated ncRNA transcripts
(PCATs) based on their fold-change in PCa
samples compared to normal tissue. PCAT-1, ∼ 1.9
kb lncRNA, is located upstream of the c-Myc
gene at chromosome 8q24 (32). Its expression
is significantly high and upregulated in most PCa
cells especially metastatic samples; furthermore,
it is mostly found in cytoplasm and in a small
amount in the nucleus of PCa cells. It has also
been reported that lncRNA PCAT-1 represses
BRCA2 involved in homologous recombination
(HR), resulting in unrepaired Double-stranded DNA
breaks (DSBs) (33). Another study revealed that
PCAT-1 with microRNAs (miR-3667-3p and miR-
34a) upregulates the c-Myc protein level, which
is essential for cell cycle progression, leading to
proliferation of prostate tumor cell (34). PCAT-5
is another oncogenic lncRNA that is regulated by
transcription factor ERG (ETS-related gene) and is
significantly associated with cell proliferation and
invasion of PCa cells. In addition, it is upregulated
in castration-resistant prostate cancer (CRPC)
tissue compared to normal prostate cells (35).
The lncRNA Prostate Ovary Testis Expressed
Family member Antisense 1 (POTEF-AS1) is the
androgen-dependent regulator that is involved in
apoptosis and toll-like receptor signaling pathways
by interacting with TLR3 and TNFSF10. In addition,
it has a fundamental role in the progression of
docetaxel-treated cells by repressing apoptosis,
resulting in chemoresistance (36).
HOXD antisense growth-associated lncRNA
(HOXD-AS1) is upregulated in PCa. A study has
reported that HOXD-AS1 regulated the expression
of target genes and promoted cell proliferation
by recruiting WDR5. This molecule is part of the
MLL1/MLL complex and has a key role in histone
H3 lysine 4 tri-methylation (H3K4me3) which is
associated with transcriptional activation (37).
Li and coworkers in 2017 reported that small
nucleolar RNA host gene 1 (SNHG1) lncRNA
promotes cell proliferation and is upregulated in
PCa. By acting as ceRNA (competing endogenous
RNA), this lncRNA suppresses the activity of miR-
199a-3p that promotes the expression of its target,
CDK7, resulting in increased cell proliferation
and cell cycle progress in PCa (38). SOCS2-AS1
(Cytokine signaling 2-antisense transcript 1) is an
androgen-induced lncRNA and regulates genes
TNFSF10, FOXM1, and CENPF, which are involved
in apoptosis and cellular proliferation in PCa.
Moreover, by repressing apoptosis, it plays a
fundamental role in the progression of CRPC (39).
CTBP1-AS, an androgen-responsive lncRNA, is
located in the AS region of C-terminal-binding
protein 1, which works as a corepressor for
the androgen receptor. By recruiting the RNA-
binding transcriptional repressor PSF and HDAC
(Histon deacetylase), this lncRNA can repress the
expression of the CTBP1 gene. Low expression
of this gene is associated with overexpression
of androgen-related genes and aberrant cell
proliferation in prostate cells which causes PCa
(40). PVT1 (Plasmacytoma Variant Translocation 1)
lncRNA was identified to be associated with miR-
146a expression. This lncRNA decreases the miR-
146a expression by increasing methylation in CpG
Island in the promoter of miR-146a. The silencing of
miR-146a suppresses apoptosis and promotes cell
viability in PCa (41). Another study by Yang and co-
authors revealed that the level of PVT1 expression
was notably high in PCa compared to normal
prostate cells. In addition, they did knockdown this
lncRNA in PCa cell lines and found the expression
of cleaved caspase-3 and c-Myc was upregulated
and downregulated, respectively. Therefore, this
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lncRNA increases cell growth in PCa in vitro and in
vivo (42).
The gene encoding TTTY15 (Testis-specific
transcript Y-linked 15) lncRNA is located at
Yq11.2. Some studies revealed that the fusion
of the TTTY15 gene with USP9Y (Ubiquitin
Specific Peptidase 9 Y-linked) gene is a potential
carcinogen in some cancers particularly in PCa
(43, 44). Xia and colelagues found that this lncRNA
is upregulated in patients with PCa compared
to normal cases. They used the CRISPR-Cas9
technique to knock down this lncRNA and reached
the conclusion that it suppressed the growth of
PCa cells in vitro and in vivo. Moreover, TTTY15
increases CDK6 and FN1 expression by acting
as a sponge for microRNA let-7 (45). A single
study reported that the expression level of THBS4-
003 (Thrombospondin 4) is significantly higher
in PCa cells compared to non-tumor ones. It
also revealed that knockdown of this lncRNA
suppressed the invasive and migratory capability
of PCa cell, the expression level of MMP-9 (matrix
metalloproteinase-9) as well as p38 (3). Further,
Jiang and colelagues found that lnc-MX1-1 (MX
Dynamin like GTPase 1) is upregulated in PCa
cells compared to adjacent normal prostate cells
using array expression profiling. By using RNAi
in LNCaP and 22Rv1 cell lines, they suppressed
the expression of this lncRNA and identified
proliferation and invasiveness of the cells were
significantly reduced. In addition, their result
indicated the significant association of this lncRNA
with clinical features of patients with PCa such as
PSA, metastasis, Gleason score, and recurrence-
free survival (17).
3.1.2. Suppressive lncRNAs in PCa
Some of the identified lncRNAs are tumor-
suppressive which show reduced expression
in PCa cell and decrease the proliferation and
migration of PCa cells through different molecular
pathways. Some main suppressive lncRNAs will
be discussed as follows. Table II presents the
further suppressive lncRNAs with their summary
of functions. BDNF-AS (brain-derived neurotrophic
factor antisense), a naturally-occurring RNA
antisense against BDNF, is downregulated in
cancers such as retinoblastoma and lung cancer
(46, 47). It was also downregulated in PSA-positive,
PSA-negative PCa cell lines as well as PCa
human tissue. Further investigation revealed that
increasing the expression of this lncRNA using
lentivirus-mediated BDNF-AS suppressed PCa
cell development, invasion, and proliferation in
two aforementioned PCa cell lines. This study
also suggested the overexpression of this lncRNA
could be considered as a potential method for
therapeutic drug for PCa (48). GAS5 (Growth
Arrest Specific 5) gene encodes a snoRNA from
its intron and a lncRNA from its exonic sequence.
The increased level of this lncRNA promotes
apoptosis and inhibits the anti-apoptotic abilities
of glucocorticoids by binding to the DNA-binding
domain of glucocorticoids (49).
A study by Pickard and colleagues using GAS5-
encoding plasmids or GAS5 siRNAs in PCa cell
lines showed that the low expression of this
lncRNA is significantly associated with increased
apoptosis and decreased survival rate in PCa
(50). In addition, a study found that this lncRNA
targets mir-103 leading to inactivation of PI3KAKT-
mTOR signaling pathway, low PCa cell growth,
and proliferation (51). A single study reported
that IGF2-AS (insulin growth factor 2 antisense)
lncRNA was downregulated in PCa cell line and
human PCa tissues. Lentivirus-induced IGF2AS
overexpression decreased xenograft development
in vivo, invasion, and proliferation of PCa cells
in vitro. Through inverse regulation of IGF2, this
lncRNA acted as an epigenetic tumor suppressor
in PCa (16). LncRNA FENDRR (FOXF1 Adjacent
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Non-Coding Developmental Regulatory RNA) is
located at 16q24.1. This lncRNA has a fundamental
role in modifying chromatin by interacting with
Trithorax group/MLL protein complexes (TrxG/MLL)
and polycomb repressive complex 2 (PRC2) (52,
53). Zhang and colleagues identified that this
lncRNA can also act as ceRNA for miR-18a-5p
which upregulates the RUNX1 expression, resulting
in decreased progression of PCa cell. Their study
also indicated that there was a negative correlation
between this lncRNA and the prognosis of PCa
(54).
Table II. Other* known suppressive lncRNAs involved in PCa
lncRNA Genomic location Summary of functions Reference
DRAIC 15q23
Knock down of this lncRNA decreases cell proliferation. It
decreases the transformation of cuboidal epithelial cells to
fibroblast-like. In addition, it decreases cellular migration
(55)
LncRNA625 15p13
Downregulated in PC3 cell line compared to normal cells. It
targets miR-432 and decrease its expression, and regulates
Wnt/β-catenin pathway. The overexpression of this lncRNA
prevents cell growth, induces cell cycle arrest at the G1/S
phase and apoptosis in PC3 cells
(56)
LOC284454 19p13.13 Downregulated in PCa samples (57)
LINC00844 10q21.1
Induces AR binding to the chromatin and regulates
androgen-regulated gene transcription. It activates the
expression of NDRG1, which is fundamental metastasis
suppressor. Furthermore, it prevents PCa progression and
invasion
(58)
PCAT29 15q23 Regulated by FOX1 and AR. It suppresses PCa migration andmetastasis (55)
PCAT14 22q11.23 Down regulation of this lncRNA is associated with metastaticprogression and Gleason score (59)
MEG3 14q32.2
Its expression is low in PCa cells compared to normal cells. It
decreases the expression of Bcl-2, increases BAX and
activates caspase3, leading to inhibition of intrinsic cell
survival pathway. It also inhibits cyclinD1and induces cell cycle
arrest in G0/G1 phase
(60)
*Refers to lncRNAs which are not mentioned in the main text
Abbreviations: AR: Androgen receptor, NDRG1: N-MYC downstream-regulated gene-1
3.2. LncRNAs in the discrimination of
BPH from PCa
BPH, another common prostate-associated
disease, is non-cancerous enlargement of prostate
characterized by over-proliferation of stromal and
epithelial cells of the transition zone (61). It affects
About 50% of males in the age range of 51-60 yr
and reaches up to 70% among the age range of
61-70 (62). The measurement of prostate-specific
antigen (PSA) has been used widely for screening
PCa; however, its level can be increased by BPH
as well (63). Therefore, using PSA is controversially
debatable (64), and finding biomarkers that can
exactly determine PCa from BPH would help
clinicians to use proper therapeutic methods for
these diseases. Several studies reported that
because of tissue-specific expression pattern of
lncRNAs, they could be considered as biomarkers
to efficiently discriminate BPH from PCa. A
study by Bayat and co-authors investigating
four lncRNAs, Prcat17.3, Prcat38, Prcat47, and
Cat2184.4, revealed low expression of lncRNA
Cat2184.4 in PCa samples compared to BPH ones.
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In contrast, lncRNAs PRCAT17.3 and PRCAT38
showed significant upregulation in PCa samples
compared to BPH ones. In addition, lncRNA
PRCAT47 showed increased expression in PCa
but not statistically significant compared to BPH
samples. They concluded that this lncRNA can be
considered as potential biomarkers to differentiate
BPH from PCa (65).
Another study investigated the expression
pattern of exosomal circulating lncRNAs in
PCa, BPH and normal samples (66). It is worth
mentioning that exosome is vesicle with 40-100
nm diameter, which has fundamental roles in the
cell-to-cell communication and cell signaling by
binding to their receptor on cells. Furthermore,
they can carry a wide variety of molecules such
as proteins, miRNAs, and lncRNAs. This structure
keeps aforementioned molecules safe from
degradation (67). This study revealed that exosomal
lncRNA SAP30L-AS1 (SAP30L Antisense RNA 1
(Head To Head)) were significantly upregulated in
BPH. However, their result showed that another
exosomal lncRNA SChLAP1 (SWI/SNF Complex
Antagonist Associated with Prostate Cancer 1)
were upregulated in PCa samples compared to
BPH and normal ones. The latter one is more
useful as biomarker for discriminating BPH from
PCa when PSA concentration is in a gray zone (66).
lncRNA-p21 is another exosomal lncRNA which
its expression pattern had been investigated in
urine samples from patients with BPH and PCa. It
is found in high level in urine samples of patients
with PCa compared to samples from BPH patients
(68).
3.3. Prostatitis
Prostatitis is inflammation of the prostate
gland that has important roles in the male
reproductive system. Although it is amendable,
its main pathophysiology and treatment in male
infertility are still unknown. It also can affect
the assisted reproduction; therefore, finding the
main pathogenesis of prostatitis and its negative
impact on sperm quantity and quality including
apoptosis and DNA integrity is indispensable (69).
A recent study by Xu and colleagues examined the
association of lncRNAGAS5 (growth arrest-specific
transcript 5), located at 1q25.1, with chronic non-
bacterial prostatitis (CNP). Their study revealed that
the expression of this lncRNA was decreased in
prostatitis tissues. In addition, they found that this
lncRNA prevented cell proliferation in prostatitis by
downregulation of COX2 expression, an enzyme
producing prostaglandins. Their study in the
GAS5-overexpressed CNP rat model showed the
overexpression of this lncRNA decreased prostate
volume, inflammatory cells count, and locomotion
score. Therefore, the overexpression of lncRNA
can reduce the injury of CNP in vivo (4).
3.4. Testicular cancer
Although TCa is generally a rare form of cancer,
with the annual incidence of approximately 1%, it
is the most prevalent cancer among men with the
age range of 14 to 44 years. Testicular germ cell
tumors (TGCT) represent nearly 98% of TCa, while
the remaining comprise stromal tumors including
Sertoli cell tumors, Leydig cell tumors, and other
more poorly defined histologic types (70, 71). Newly
identified TC are responsive to treatment; however,
therapeutic outcomes of theses tumors in high
stages are not sufficient (72, 73). Therefore, finding
molecular pathways and their regulatory elements
involved in the progression and growth of TCa cells
such as lncRNA would lead to the identification
of the best treatment for TCa. A recent study
used NCCIT cell lines (Human testicular embryonic
carcinoma cells), a pluripotent extragonadal germ
cell tumor cell line, to determine the effect of
lncRNA Gm2044 on the growth and proliferation
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of TCa cells. It revealed that the overexpression
of this lncRNA prohibited cell proliferation in
vitro. In addition, its results showed this effect
was mediated by the miR-202-Rbfox2 pathway
(74). LncRNA OIP5-AS1 (Opa-interacting protein 5
antisense RNA 1), located at 15q15.1, is another
lncRNA that was shown to be overexpressed
and promote cell proliferation in many cancers
(75). This lncRNA is highly overexpressed in
TGCT compared to other many cancers such
as thyroid, prostate, pheochromocytoma, and
paraganglioma (76). Based on the study by
Rezaie and co-authors lncRNA LINC-ROR (Long
Intergenic Non-Protein Coding RNA, Regulator
Of Reprogramming) was highly expressed in
testicular tumor tissues compared to control cell
lines (NT2) (77). This lncRNA is located at 18q21
and is involved in embryonic stem cells (ESC)
maintenance (78). Moreover, this lncRNA interacts
with heterogeneous nuclear ribonucleoprotein I
and suppresses p53 activated by DNA damage
(79).
3.5. Varicocele
Varicocele, a main abnormality contributing
to male infertility, is an abnormal dilation of
pampiniform venous plexus in the scrotum
and is prevalent among 20% of adult and
adolescent male (80). It causes increased
oxidative stress, apoptosis, venous pressure,
and temperature resulting in testicular and
sperm damage (81). Although many genetics
factors such as chromosome alteration and
epigenetic changes have been identified to
be associated with Varicocele, however, its
main molecular mechanism is still unknown
(82). lncRNAs as a functional modulator of
biological processes may have important roles
in the pathogenesis of the disease. The lncRNA
gadd7 (growth arrested DNA-damage inducible
gene 7), a 754−nt polyadenylated lncRNA, is
overexpressed after DNA damage and growth
arrest signal. Its overexpression is associated with
suppressed cell growth (83, 84). Furthermore, it
is the modulator of endoplasmic reticulum stress
and lipid-induced oxidative (85). A single study
analyzed the expression level of this lncRNA
in the ejaculated spermatozoa of patients with
Varicocele and found that the expression level
lncRNA gadd7 is negatively associated with sperm
count. It also used mouse germ cell lines GC-1 and
GC-2 transfected with either pcDNA3.1-gadd7 or
negative control plasmid to investigate the effect
of this lncRNA overexpression on cell features. Its
result indicated the overexpression of this lncRNA
suppressed cell proliferation and increased cell
apoptosis. In addition, the study showed that
gadd7 induced by stress can cause cell death
through upregulation of Bax and downregulation
of Bcl2, which are pro-apoptotic and anti-apoptotic
regulators, respectively (86).
3.6. Sperm abnormalities
Male infertility can also be ascribed to
uniform testicular maturation arrest (MA) and
different types of sperm abnormalities such as
oligozoospermia, non-obstructive azoospermia,
AZS, and teratozoospermia (87). Spermatogenesis
is a complex process regulated by different
genes, proteins, and transcriptional network
including ncRNAs. Based on the wide ability of
lncRNA in proliferation, differentiation, and self-
renewal of SSC, they have fundamental roles
in spermatogenesis regulation (88). LncRNA
HOTAIR (HOX Transcript Antisense Intergenic
RNA), located at 12q13.13, is one of the well-
studied lncRNA in many diseases and involved
in chromatin regulation by binding to Polycomb
repressive complex 2 (PRC2) (89). In addition,
it plays a key role in epigenetic regulation by
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interacting with the lysine-specific demethylase
1 (LSD1), Enhancer of Zeste homolog 2 (EZH2)
,and methyltransferase specific to histone 3 lysine
27 (90). Zhang and colleagues investigated the
expression of this lncRNA in the samples from
patients with AZS and oligoasthenozoospermia,
and found it had a low expression in AZS and
oligoasthenozoospermia compared to normal
samples. Furthermore, their results indicated that
the low expression of HOTAIR is associated with
low expression NRF2 (Nuclear factor erythroid
2-related factor 2) gene. HOTAIR is responsible
for histone H4 acetylation in the NRF2 gene
promoter, which leads to its activation (91). Since
the expression level of NRF2 is associated with
sperm quality and antioxidant gene expression
(92), HOTAIR may protect spermatozoa against
antioxidant activity (91). Another study analyzed the
expression profile of lncRNA in AZS and normal
sperm samples. The gene ontology and pathway
analysis revealed that differentially expressed
lncRNA in AZS and normal samples were related to
sperm function and spermatogenesis. Moreover,
among all identified differentially expressed
lncRNAs, the expression level of three lncRNA
including lnc32058, lnc09522, and lnc98487
were significantly correlated with sperm motility
(93).
4. Conclusion
In conclusion, this review emphasizes the
identified lncRNAs and their functions in
male reproductive disorders including PCa,
BPH, prostatitis, TCa, varicocele, and sperm
abnormalities. With the advent of state-of-the-
art molecular and genomics techniques such
as high-throughput sequencing, thousands of
lncRNA have been identified in susceptibility
to different diseases. However, their main
mechanisms and molecular pathways are still
unknown and need more functional and in vitro
studies. Identification of differentially expressed
lncRNA in each disease can pave the way toward
developing unique biomarker, approaches to treat
diseases, as well as increase efficiency of assisted
reproductive technologies. In addition, lncRNA
can be considered as precious indicator of sperm
quality.
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